Retatrutide

Retatrutide (originally known as LY-3437943) is a highly effective, investigative multi-receptor agonist developed for the treatment of severe obesity and type 2 diabetes. By simultaneously activating the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R), it works comprehensively to suppress appetite, enhance feelings of fullness, delay gastric emptying, and significantly increase energy expenditure. Clinical data indicates it provides substantial weight reduction profiles and highly robust glycemic control compared to earlier single or dual-receptor therapies.

Retatrutide is an experimental, synthetic triple-agonist peptide designed to target three primary metabolic receptors: GLP-1, GIP, and glucagon.

Store in a cool, dry environment: -20°C.